NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis $0.67 -0.02 (-2.19%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.70 +0.03 (+4.53%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adicet Bio Stock (NASDAQ:ACET) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adicet Bio alerts:Sign Up Key Stats Today's Range$0.66▼$0.7050-Day Range$0.61▼$0.8252-Week Range$0.45▼$1.64Volume271,773 shsAverage Volume355,689 shsMarket Capitalization$55.47 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts. Read More Adicet Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreACET MarketRank™: Adicet Bio scored higher than 57% of companies evaluated by MarketBeat, and ranked 423rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAdicet Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAdicet Bio has only been the subject of 1 research reports in the past 90 days.Read more about Adicet Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adicet Bio are expected to decrease in the coming year, from ($1.39) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adicet Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.55% of the outstanding shares of Adicet Bio have been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Adicet Bio has recently increased by 13.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.55% of the outstanding shares of Adicet Bio have been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Adicet Bio has recently increased by 13.25%, indicating that investor sentiment is decreasing significantly. News and Social Media4.0 / 5News Sentiment1.26 News SentimentAdicet Bio has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adicet Bio this week, compared to 2 articles on an average week.Search Interest15 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.MarketBeat Follows4 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Adicet Bio is held by insiders.Percentage Held by Institutions83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adicet Bio's insider trading history. Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Stock News HeadlinesQ2 Earnings Forecast for Adicet Bio Issued By HC WainwrightJuly 27, 2025 | americanbankingnews.comAdicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune DiseasesJuly 24, 2025 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Adicet Bio, Inc. (ACET) Balance Sheet - Yahoo FinanceJune 28, 2025 | finance.yahoo.comAdicet Bio, Inc. (ACET) Balance Sheet - Yahoo FinanceJune 28, 2025 | finance.yahoo.comAdicet Bio’s SWOT analysis: gamma-delta T cell therapy stock faces pivotal yearMay 28, 2025 | uk.investing.comAdicet Bio Stock Price, Quotes and Forecasts | NASDAQ:ACET | BenzingaMay 8, 2025 | benzinga.comAdicet Bio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 6, 2025 | businesswire.comSee More Headlines ACET Stock Analysis - Frequently Asked Questions How have ACET shares performed this year? Adicet Bio's stock was trading at $0.9620 at the beginning of 2025. Since then, ACET stock has decreased by 30.3% and is now trading at $0.6706. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.03. Who are Adicet Bio's major shareholders? Top institutional investors of Adicet Bio include Vontobel Holding Ltd. (0.10%). Insiders that own company stock include Orbimed Advisors Llc, Don Healey, Chen Schor, Blake Aftab and Steve Dubin. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adicet Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT). Company Calendar Last Earnings5/06/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:ACET CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Adicet Bio$6.00 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+794.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$117.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-59.05% Return on Assets-50.66% Debt Debt-to-Equity RatioN/A Current Ratio9.34 Quick Ratio9.34 Sales & Book Value Annual Sales$24.99 million Price / Sales2.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book0.30Miscellaneous Outstanding Shares82,710,000Free Float76,259,000Market Cap$55.47 million OptionableOptionable Beta1.59 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ACET) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.